Author： Conti David V. Lee Won Li Dalin Liu Jinghua Van Den Berg David Thomas Paul D. Bergen Andrew W. Swan Gary E. Tyndale Rachel F. Benowitz Neal L. Lerman Caryn
Publisher： Oxford University Press
ISSN： 1460-2083
Source： Human Molecular Genetics, Vol.17, Iss.18, 2008-09, pp. : 2834-2848
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Although the efficacy of pharmacotherapy for tobacco dependence has been previously demonstrated, there is substantial variability among individuals in treatment response. We performed a systems-based candidate gene study of 1295 single nucleotide polymorphisms (SNPs) in 58 genes within the neuronal nicotinic receptor and dopamine systems to investigate their role in smoking cessation in a bupropion placebo-controlled randomized clinical trial. Putative functional variants were supplemented with tagSNPs within each gene. We used global tests of main effects and treatment interactions, adjusting the P-values for multiple correlated tests. An SNP (rs2072661) in the 3 UTR region of the 2 nicotinic acetylcholine receptor subunit (CHRNB2) has an impact on abstinence rates at the end of treatment (adjusted P 0.01) and after a 6-month follow-up period (adjusted P 0.0002). This latter P-value is also significant with adjustment for the number of genes tested. Independent of treatment at 6-month follow-up, individuals carrying the minor allele have substantially decreased the odds of quitting (OR 0.31; 95 CI 0.180.55). Effect of estimates indicate that the treatment is more effective for individuals with the wild-type (OR 2.14, 95 CI 1.203.81) compared with individuals carrying the minor allele (OR 0.83, 95 CI 0.322.19), although this difference is only suggestive (P 0.10). Furthermore, this SNP demonstrated a role in the time to relapse (P 0.0002) and an impact on withdrawal symptoms at target quit date (TQD) (P 0.0009). Overall, while our results indicate strong evidence for CHRNB2 in ability to quit smoking, these results require replication in an independent sample.
Related content
Access to resources
Recommend
By Lou Xiang-Yang Ma Jennie Payne Thomas Beuten Joke Crew Karen Li Ming
Human Genetics, Vol. 120, Iss. 3, 2006-10 ,pp. :
By Saccone Scott F. Hinrichs Anthony L. Chase Gary A. Konvicka Karel Madden Pamela A.F. Breslau Naomi Johnson Eric O. Hatsukami Dorothy Pomerleau Ovide Swan Gary E. Goate Alison M. Rutter Joni Bertelsen Sarah Fox Louis Fugman Douglas Martin Nicholas G. Montgomery Grant W. Wang Jen C. Ballinger Dennis G. Rice John P. Bierut Laura Jean
Human Molecular Genetics, Vol. 16, Iss. 1, 2007-01 ,pp. :
By Freathy Rachel M. Ring Susan M. Shields Beverley Galobardes Bruna Knight Beatrice Weedon Michael N. Smith George Davey Frayling Timothy M. Hattersley Andrew T.
Human Molecular Genetics, Vol. 18, Iss. 15, 2009-08 ,pp. :
By Tyrrell Jessica Huikari Ville Christie Jennifer T. Cavadino Alana Bakker Rachel Brion Marie-Jo A. Geller Frank Paternoster Lavinia Myhre Ronny Potter Catherine Johnson Paul C.D. Ebrahim Shah Feenstra Bjarke Hartikainen Anna-Liisa Hattersley Andrew T. Hofman Albert Kaakinen Marika Lowe Lynn P. Magnus Per McConnachie Alex Melbye Mads Ng Jane W.Y. Nohr Ellen A. Power Chris Ring Susan M. Sebert Sylvain P. Sengpiel Verena Taal H. Rob Watt Graham C.M. Sattar Naveed Relton Caroline L. Jacobsson Bo Frayling Timothy M. Sørensen Thorkild I.A. Murray Jeffrey C. Lawlor Debbie A. Pennell Craig E. Jaddoe Vincent W.V. Hypponen Elina Lowe William L. Jarvelin Marjo-Riitta Davey Smith George Freathy Rachel M.
Human Molecular Genetics, Vol. 21, Iss. 24, 2012-12 ,pp. :